PR Newswire
THE BIOTECH GROWTH TRUST PLC
NET ASSET VALUE
The estimated un-audited net asset value per share, calculated in accordance with the guidelines of the Association of Investment Companies, for The Biotech Growth Trust PLC at the close of business on 21 November 2024 was 981.14p (cum income).
For and on behalf of the Board
Frostrow Capital LLP
Secretary
22 November 2024
THE BIOTECH GROWTH TRUST PLC
NET ASSET VALUE
The estimated un-audited net asset value per share, calculated in accordance with the guidelines of the Association of Investment Companies, for The Biotech Growth Trust PLC at the close of business on 20 November 2024 was 983.55p (cum income).
For and on behalf of the Board
Frostrow Capital LLP
Secretary
21 November 2024
THE BIOTECH GROWTH TRUST PLC
NET ASSET VALUE
The estimated un-audited net asset value per share, calculated in accordance with the guidelines of the Association of Investment Companies, for The Biotech Growth Trust PLC at the close of business on 19 November 2024 was 969.00p (cum income).
For and on behalf of the Board
Frostrow Capital LLP
Secretary
20 November 2024
THE BIOTECH GROWTH TRUST PLC
NET ASSET VALUE
The estimated un-audited net asset value per share, calculated in accordance with the guidelines of the Association of Investment Companies, for The Biotech Growth Trust PLC at the close of business on 18 November 2024 was 963.94p (cum income).
For and on behalf of the Board
Frostrow Capital LLP
Secretary
19 November 2024
THE BIOTECH GROWTH TRUST PLC
NET ASSET VALUE
The estimated un-audited net asset value per share, calculated in accordance with the guidelines of the Association of Investment Companies, for The Biotech Growth Trust PLC at the close of business on 15 November 2024 was 982.55p (cum income).
For and on behalf of the Board
Frostrow Capital LLP
Secretary
18 November 2024
For immediate release
15 November 2024
THE BIOTECH GROWTH TRUST PLC
(the "Company")
MARKET PURCHASE OF COMPANY'S OWN SHARES
Notification is given, pursuant to the authority granted at the Annual General Meeting of the Company held on 18 July 2024 to make market purchases of the Company's own shares up to an aggregate maximum of 4,929,790 that a market total of 75,000 Ordinary shares of 25p each in the capital of the Company were purchased today for cancellation by the Company at a price of 988.98 pence per share.
Following this transaction, the Company hereby notifies the market that the total number of Ordinary shares that the Company has in issue, less the total number of Ordinary shares bought back for cancellation by the Company following such purchase, and therefore, the total number of voting rights in the Company is 31,519,676. The Company does not currently hold any Ordinary shares in treasury.
The figure of 31,519,676 may be used by shareholders as the denominator for the calculation by which they may determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
For and on behalf of
Frostrow Capital LLP
Company Secretary
For further information, please contact:
Katherine Manson
Frostrow Capital LLP
Tel: 020 3709 8734
THE BIOTECH GROWTH TRUST PLC
NET ASSET VALUE
The estimated un-audited net asset value per share, calculated in accordance with the guidelines of the Association of Investment Companies, for The Biotech Growth Trust PLC at the close of business on 14 November 2024 was 1044.06p (cum income).
For and on behalf of the Board
Frostrow Capital LLP
Secretary
15 November 2024
The Biotech Growth Trust PLC
(the "Company")
15 November 2024
Monthly Fact Sheet as at 31 October 2024
The Biotech Growth Trust PLC Fact Sheet as at 31 October 2024 has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism and on the Company's website, www.biotechgt.com.
- END-
Frostrow Capital LLP
Company Secretary
Tel: 020 3709 8734
THE BIOTECH GROWTH TRUST PLC
NET ASSET VALUE
The estimated un-audited net asset value per share, calculated in accordance with the guidelines of the Association of Investment Companies, for The Biotech Growth Trust PLC at the close of business on 13 November 2024 was 1060.93p (cum income).
For and on behalf of the Board
Frostrow Capital LLP
Secretary
14 November 2024
THE BIOTECH GROWTH TRUST PLC
NET ASSET VALUE
The estimated un-audited net asset value per share, calculated in accordance with the guidelines of the Association of Investment Companies, for The Biotech Growth Trust PLC at the close of business on 12 November 2024 was 1068.54p (cum income).
For and on behalf of the Board
Frostrow Capital LLP
Secretary
13 November 2024
THE BIOTECH GROWTH TRUST PLC
NET ASSET VALUE
The estimated un-audited net asset value per share, calculated in accordance with the guidelines of the Association of Investment Companies, for The Biotech Growth Trust PLC at the close of business on 11 November 2024 was 1114.95p (cum income).
For and on behalf of the Board
Frostrow Capital LLP
Secretary
12 November 2024
THE BIOTECH GROWTH TRUST PLC
NET ASSET VALUE
The estimated un-audited net asset value per share, calculated in accordance with the guidelines of the Association of Investment Companies, for The Biotech Growth Trust PLC at the close of business on 8 November 2024 was 1110.66p (cum income).
For and on behalf of the Board
Frostrow Capital LLP
Secretary
11 November 2024
For immediate release
8 November 2024
THE BIOTECH GROWTH TRUST PLC
(the "Company")
MARKET PURCHASE OF COMPANY'S OWN SHARES
Notification is given, pursuant to the authority granted at the Annual General Meeting of the Company held on 18 July 2024 to make market purchases of the Company's own shares up to an aggregate maximum of 4,929,790 that a market total of 50,000 Ordinary shares of 25p each in the capital of the Company were purchased today for cancellation by the Company at a price of 1034.66 pence per share.
Following this transaction, the Company hereby notifies the market that the total number of Ordinary shares that the Company has in issue, less the total number of Ordinary shares bought back for cancellation by the Company following such purchase, and therefore, the total number of voting rights in the Company is 31,594,676. The Company does not currently hold any Ordinary shares in treasury.
The figure of 31,594,676 may be used by shareholders as the denominator for the calculation by which they may determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
For and on behalf of
Frostrow Capital LLP
Company Secretary
For further information, please contact:
Katherine Manson
Frostrow Capital LLP
Tel: 020 3709 8734
THE BIOTECH GROWTH TRUST PLC
NET ASSET VALUE
The estimated un-audited net asset value per share, calculated in accordance with the guidelines of the Association of Investment Companies, for The Biotech Growth Trust PLC at the close of business on 7 November 2024 was 1101.97p (cum income).
For and on behalf of the Board
Frostrow Capital LLP
Secretary
08 November 2024
THE BIOTECH GROWTH TRUST PLC
NET ASSET VALUE
The estimated un-audited net asset value per share, calculated in accordance with the guidelines of the Association of Investment Companies, for The Biotech Growth Trust PLC at the close of business on 6 November 2024 was 1122.82p (cum income).
For and on behalf of the Board
Frostrow Capital LLP
Secretary
07 November 2024
THE BIOTECH GROWTH TRUST PLC
NET ASSET VALUE
The estimated un-audited net asset value per share, calculated in accordance with the guidelines of the Association of Investment Companies, for The Biotech Growth Trust PLC at the close of business on 5 November 2024 was 1097.18p (cum income).
For and on behalf of the Board
Frostrow Capital LLP
Secretary
06 November 2024
THE BIOTECH GROWTH TRUST PLC
NET ASSET VALUE
The estimated un-audited net asset value per share, calculated in accordance with the guidelines of the Association of Investment Companies, for The Biotech Growth Trust PLC at the close of business on 4 November 2024 was 1090.02p (cum income).
For and on behalf of the Board
Frostrow Capital LLP
Secretary
05 November 2024
THE BIOTECH GROWTH TRUST PLC
NET ASSET VALUE
The estimated un-audited net asset value per share, calculated in accordance with the guidelines of the Association of Investment Companies, for The Biotech Growth Trust PLC at the close of business on 1 November 2024 was 1084.24p (cum income).
For and on behalf of the Board
Frostrow Capital LLP
Secretary
04 November 2024
THE BIOTECH GROWTH TRUST PLC
NET ASSET VALUE
The estimated un-audited net asset value per share, calculated in accordance with the guidelines of the Association of Investment Companies, for The Biotech Growth Trust PLC at the close of business on 31 October 2024 was 1085.60p (cum income).
For and on behalf of the Board
Frostrow Capital LLP
Secretary
01 November 2024
The Biotech Growth Trust PLC
01 November 2024
The Biotech Growth Trust PLC
Voting Rights and Capital
In accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, The Biotech Growth Trust PLC (the "Company") announces the following:
As at 31 October 2024, the Company capital consists of ordinary shares of 25p with each ordinary share holding one voting right. The total number of ordinary shares in issue is 31,644,676. The Company has no ordinary shares in Treasury.
Therefore, the total number of voting rights in the Company is 31,644,676.
The above figure (31,644,676) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in the Company or a change to their interest in the Company, under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
- END -
Frostrow Capital LLP
Company Secretary
Tel: 0203 709 8734
The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.
RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.
Note: The newswire cross-link panel at the top allows you to quickly and easily access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted searches.
On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.